The Role of Correction of Anaemia in Patients with Congestive Heart Failure: A Short Review
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Many patients with Congestive Heart Failure (CHF) are anaemic. This anaemia is associated with more severe CHF and a higher incidence of mortality, hospitalisation and morbidity. The only way to prove that the anaemia is causing this worsening of CHF is to correct it. We review here some of the published papers about correction of anaemia. Many studies show a positive effect of Erythropoietin (EPO) or its' derivatives when administered in combination with oral or IV iron, with improvements in left and right ventricular systolic and diastolic function, dilation and hypertrophy and renal function. In addition, a reduction in hospitalisations, diuretic dose, pulmonary artery pressure, plasma volume, heart rate, serum Brain Natriuretic Peptide levels, the inflammatory marker Interleukin 6, soluble Fas ligand—a mediator of apoptosis, and improvements in New York Heart Association class, exercise capacity, oxygen utilization, caloric intake, Quality of Life and the activity of Endothelial Progenitor Cells, have been observed. Iron deficiency may also play an important role in this anaemia, since improvements in CHF have also been reported following treatment with IV iron alone. However, until the ongoing large placebo-controlled studies of the EPO derivative darbepoetin or IV iron are completed, we will not know whether these treatments really influence CHF outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
The non‐haematopoietic biological effects of erythropoietin
Arcasoy, M. O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07014.x · Cited by 347
Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure
Bolger, A. P., Bartlett, F. R., Penston, H. S., O’Leary, J., Pollock, N., Kaprielian, R., & Chapman, C. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.015 · Cited by 292 · cited 1×
“As shown in two recent studies, CHF patients have been shown to respond to treatment of functional iron deficiency with IV iron, improvements in Hb, Left Ventricular Ejection Fraction (LVEF), NYHA class, Quality of Life, exercise capacity and renal function, and reduced heart rate, BNP, CRP and hospitalisation rates h…”
Result
Research works printed but not linked: 47
- Hunt, 2005, ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article, J Am Coll Cardiol, 46, 1116, 10.1016/j.jacc.2005.08.023 · DOI · Paper page
- Silverberg, 2006, The interaction between heart failure and other heart disease and anemia, Semin Nephrol, 26, 296, 10.1016/j.semnephrol.2006.05.006 · DOI
- Lindenfeld, 2005, Prevalence of anemia and the effects on mortality in patients with heart failure, Am Heart J, 149, 391, 10.1016/j.ahj.2004.08.039 · DOI
- Tang, 2008, The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes, Heart Fail Rev, 13, 387, 10.1007/s10741-008-9089-7 · DOI
- Anand, 2005, Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-Heft, Circulation, 112, 1121, 10.1161/CIRCULATIONAHA.104.512988 · DOI · Paper page
- Komajda, 2006, The impact of new onset anemia on morbidity and mortality in chronic heart failure: results from COMET, Eur Heart J, 27, 1441, 10.1093/eurheartj/ehl012 · DOI · Paper page
- Tang, 2008, Evaluation and long-term prognosis of new-onset, transient and persistent anemia in ambulatory patients with chronic heart failure, J Am Coll Cardiol, 51, 569, 10.1016/j.jacc.2007.07.094 · DOI · Paper page
- Silverberg, 2000, The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations, J Am Coll Cardiol, 35, 1737, 10.1016/S0735-1097(00)00613-6 · DOI · Paper page
- Silverberg, 2003, The effect of correction of anemia in diabetics and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron, Nephrol Dial Transplant, 18, 141, 10.1093/ndt/18.1.141 · DOI · Paper page
- Vaisman, 2004, Correction of anemia in patients with congestive heart failure increases resting energy expenditure, Clin Nutr, 23, 355, 10.1016/j.clnu.2003.08.005 · DOI
- Silverberg, 2005, Effects of treatment with EPO beta on outcomes in patients with anaemia and chronic renal failure, Kidney Blood Press Res, 28, 41, 10.1159/000081621 · DOI
- George, 2005, Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner, Cardiovasc Res, 68, 299, 10.1016/j.cardiores.2005.06.022 · DOI
- Zilberman, 2007, Improvement of anemia with erythropoietin and intravenous iron reduces Sleep Related Breathing Disorders (SRBD) and improves daytime sleepiness in anemic congestive heart failure (CHF) patients, Am Heart J, 154, 870, 10.1016/j.ahj.2007.07.034 · DOI
- Silverberg, 2001, The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study, J Am Coll Cardiol, 37, 1775, 10.1016/S0735-1097(01)01248-7 · DOI · Paper page
- Pappas, 2007, Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance, Cardiovasc Drugs Ther, 22, 37, 10.1007/s10557-007-6075-6 · DOI
- Mancini, 2003, Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure, Circulation, 107, 294, 10.1161/01.CIR.0000044914.42696.6A · DOI · Paper page
- Kourea, 2008, Effects of darbepoetin-alfa on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin 10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure, Atherosclerosis, 199, 215, 10.1016/j.atherosclerosis.2007.09.039 · DOI
- Parissis, 2008, Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy, Am Heart J, 155, 751.e1, 10.1016/j.ahj.2008.01.016 · DOI
- Palazzuoli, 2006, Erythropoietin improves anemia, exercise tolerance, and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia, Am Heart J, 152, 1096.e9, 10.1016/j.ahj.2006.08.005 · DOI · Paper page
- Palazzuoli, 2007, Effects of beta erythropoietin on left ventricular remodeling, systolic function and beta-type natriuretic peptide levels in patients with cardio-renal anemia syndrome, Am Heart J, 154, 645.e9, 10.1016/j.ahj.2007.07.022 · DOI
- Ghali, 2008, Randomized double blind trial of darbepoetin alpha treatment in patients with symptomatic heart failure and anemia, Circulation, 117, 526, 10.1161/CIRCULATIONAHA.107.698514 · DOI · Paper page
- Van Veldhuisen, 2007, Randomized double blind placebo-controlled trial to evaluate the effect of two dosing regimens of darbepoetin alpha in patients with heart failure and anaemia, Eur Heart J, 28, 2208, 10.1093/eurheartj/ehm328 · DOI · Paper page
- Ponikowski, 2007, Effect of darbepoetin alpha on exercise tolerance in anemic patients with symptomatic chronic heart failure, J Am Coll Cardiol, 49, 753, 10.1016/j.jacc.2006.11.024 · DOI · Paper page
- Bennett, 2008, Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia, JAMA, 299, 914, 10.1001/jama.299.8.914 · DOI · Paper page
- Rizzo, 2008, Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology Clinical Practice Guideline Update, Blood, 111, 25, 10.1182/blood-2007-08-109488 · DOI · Paper page
- Drueke, 2006, Normalization of haemoglobin level in patients with chronic kidney disease and anemia, N Engl J Med, 355, 2071, 10.1056/NEJMoa062276 · DOI · Paper page
- Strippoli, 2007, Haemoglobin targets: we were wrong, time to move on, Lancet, 369, 346, 10.1016/S0140-6736(07)60165-2 · DOI
- Phrommintikul, 2007, Mortality and target hemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis, Lancet, 369, 381, 10.1016/S0140-6736(07)60194-9 · DOI · Paper page
- Toblli, 2007, Intravenous iron reduces NT-pro-BNP in anemic patients with chronic heart failure and renal insufficiency, J Am Coll Cardiol, 50, 1657, 10.1016/j.jacc.2007.07.029 · DOI · Paper page
- Okonko, 2008, Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency, J Am Coll Cardiol, 51, 103, 10.1016/j.jacc.2007.09.036 · DOI · Paper page
- Opasich, 2005, Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure, Eur Heart J, 26, 2232, 10.1093/eurheartj/ehi388 · DOI · Paper page
- Nanas, 2006, Etiology of anemia in patients with advanced heart failure, J Am Coll Cardiol, 48, 2485, 10.1016/j.jacc.2006.08.034 · DOI · Paper page
- Anand, 2008, Heart Failure and anemia: mechanisms and pathophysiology, Heart Fail Rev, 13, 379, 10.1007/s10741-008-9088-8 · DOI
- Coyne, 2007, Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin Saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study, J Am Soc Nephrol, 8, 975, 10.1681/ASN.2006091034 · DOI · Paper page
- Kapoian, 2008, Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin, J Am Soc Nephrol, 19, 372, 10.1681/ASN.2007050606 · DOI · Paper page
- Hedenus, 2007, Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study, Leukemia, 21, 627, 10.1038/sj.leu.2404562 · DOI · Paper page
- Henry, 2007, Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy, Oncologist, 12, 231, 10.1634/theoncologist.12-2-231 · DOI · Paper page
- Auerbach, 2004, Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label randomized trial, J Clin Oncol, 22, 1301, 10.1200/JCO.2004.08.119 · DOI · Paper page
- Gotloib, 2006, Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron, J Nephrol, 19, 161
- Mircescu, 2006, Intravenous iron supplementation for the treatment of anemia in predialyzed chronic renal failure patients, Nephrol Dial Transplant, 21, 120, 10.1093/ndt/gfi087 · DOI
- Pfeffer, 2007, An ongoing study of anemia correction in chronic kidney disease, N Engl J Med, 356, 959, 10.1056/NEJMc066568 · DOI
- van Veldhuisen, 2007, Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomized outcome trial, Eur Heart J, 9, 110
- Singh, 2008, The optimal hemoglobin in dialysis patients—a critical review, Sem Dial, 21, 1, 10.1111/j.1525-139X.2007.00329.x · DOI
- US Food and Drug Administration: Information for Healthcare Professionals Erythropoiesis Stimulating Agents (ESA), 2007, FDA Alert
- Young, 2008, Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry), Am J Cardiol, 101, 223, 10.1016/j.amjcard.2007.07.067 · DOI · Paper page
- Owan, 2006, Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients, J Cardiac Fail, 12, 257, 10.1016/j.cardfail.2006.02.007 · DOI
- De Luca, 2008, Overview of emerging pharmacologic agents for acute heart failure syndromes, Eur J Heart Fail, 10, 201, 10.1016/j.ejheart.2008.01.002 · DOI
Cited by
Iron deficiency in chronic heart failure: an international pooled analysis
Klip, I. T., Comin-Colet, J., Voors, A. A., Ponikowski, P., Enjuanes, C., Banasiak, W., Lok, D. J., Rosentryt, P., Torrens, A., Polonski, L., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.01.017 · Cited by 736
Iron deficiency: an ominous sign in patients with systolic chronic heart failure
Jankowska, E. A., Rozentryt, P., Witkowska, A., Nowak, J., Hartmann, O., Ponikowska, B., Borodulin-Nadzieja, L., Banasiak, W., Polonski, L., Filippatos, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq158 · Cited by 652
Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives
Jankowska, E. A., von Haehling, S., Anker, S. D., Macdougall, I. C., & Ponikowski, P. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs224 · Cited by 399
Silverberg, D. S. (2011) · Heart Failure Reviews · doi:10.1007/s10741-010-9194-2 · Cited by 48
Self-citation
Metadata
- Authors
- Silverberg, D. S., Wexlerb, D., Iaina, A., & Schwartz, D.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-09-01
- Volume
- 10
- Issue
- 9
- Pages
- 819-823
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2162006209
- Cited by
- 47
- References
- 4
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Correction of Anaemia in Patients with Congestive Heart Failure: A Short Review. https://app.cochat.ai/papers/10.1016/j.ejheart.2008.06.015
- The paper
- Silverberg, D. S., Wexlerb, D., Iaina, A., & Schwartz, D. (2008). The Role of Correction of Anaemia in Patients with Congestive Heart Failure: A Short Review. European Journal of Heart Failure. https://doi.org/10.1016/j.ejheart.2008.06.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.